Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers have launched a new study to improve our understanding of monkeypox disease. The first patients have now been recruited at Hôpitaux Universitaires de Genève (HUG) in Switzerland

Monkeypox is a relatively rare disease. In most patients it causes a painful rash, and other symptoms in some. Rarely, it can cause complications that can be fatal. Since its discovery in the late 1950’s, outbreaks have been occurring in communities in Central and West Africa, but there is now more spread in the European region.

This new study builds upon work already underway in the Central African Republic to better characterise the disease in countries where recent spread has been reported. Patients in ten participating countries – United Kingdom, Switzerland, Belgium, France, Ireland, Italy, Netherlands, Norway, Portugal and Spain – will provide information to the study team on their symptoms and responses to treatments, and will be monitored for the speed of their recovery and any complications. Patients can be enrolled whether they are cared for in hospital or at home, and whether or not they receive treatments (such as the antiviral tecovirimat) to treat monkeypox. There is hope to add further countries to the study, and the study materials have been made freely available to any institution in any country who wishes to take part.

Professor Piero Olliaro of the University of Oxford and Chief Investigator for the trial said “I am delighted that in the space of just a few weeks a study has been launched in Europe, overcoming regulatory and operational challenges through cooperation between researchers. However, this should not make us forget the investments to be made in African countries where this hitherto largely neglected disease is endemic".

Professor Alexandra Calmy at HUG added "thanks to this unprecedented international collaboration, we will contribute to a better understanding, and therefore to adjusting our response against this disease, that is posing a significant challenge because of its rapid geographic expansion".

Professor Xavier Lescure from the Infectious diseases department at Bichat hospital - Assistance Publique - Hôpitaux de Paris and Université Paris cité, and investigator for France with ANRS-Emerging Infectious Diseases stated “there is an urgent need for us to better understand this neglected disease - so that we can offer patients and their doctors and families certainty about their illness, and better understand which treatments might offer the best chance of early recovery. This study is an important example of how collaborative science can help us reach these answers, and we are grateful to the patients and families of those who will be taking part.”

The study has been approved in the UK, France, and Switzerland as an observational study, and is undergoing regulatory review by participating EU Member States as a clinical trial at low-intervention, coordinated centrally by the EMA.  Collaboration occurs through the EU-Response network in the European Union [Horizon 2020 grant 101015736] and under the Ecraid (European Clinical Research Alliance on Infectious diseases) [Horizon 2020 grant 965313] umbrella. The University of Oxford is the overall coordinating centre and UK sponsor, with ANRS | Emerging infectious diseases and HUG (Hôpitaux Universitaires de Genève) as coordinating centres for EU/EEA and Switzerland, respectively. The study is partly supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z], the Bill & Melinda Gates Foundation [OPP1209135].

Contact  for further information.

Similar stories

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden

MQRG team delivers training in Mozambique and Ghana

IDDO’s Medicine Quality Research Group delivered in-person training in researchers in Mozambique and Ghana to support a study into the quality of three antibiotics.

Studying the MSc IHTM 2022/23

MSc IHTM sets out to attract individuals from low resource contexts who are looking to gain the skills and experience to help shape global health in the future. This year 23 students make up the cohort bringing the running total over the eight years of the course to 175 students from 56 countries, the majority of which are LMICs.

The University of Oxford launches fully online Postgraduate Diploma in Global Health Research to tackle inequities in health research leadership

Beginning in October 2023, the Postgraduate Diploma in Global Health Research is specifically targeted at researchers and clinicians in low income countries, and will offer accessibility never previously available. It is the University’s first academic qualification designed to be taken wholly online and will transform Oxford’s ability to reach and train researchers in the most challenging of settings. By removing this significant barrier to access, the postgraduate diploma aims to strengthen health workforces’ research capacity, regardless of location and context, to meet ongoing and emerging global health challenges and crises.